← Back to Home

Testing Multiple Drugs in One Trial: UK Launches Alzheimer’s Drug Repurposing Study

AD-SMART has recruited its first participants and will initially test metformin and atomoxetine. By sharing a placebo group and using interim analyses, the team hopes to shorten the wait for effective treatments, but whether either drug can improve patients’ lives remains for clinical results to answer.

By SURL BioNews

For people with Alzheimer’s disease and their families, waiting for a candidate drug to complete a trial often means years of changes in their condition. The newly launched AD-SMART study in the UK aims to change the pace of setting up separate trials and waiting for answers one at a time: multiple drugs will be tested within a single platform, with the research direction adjusted as evidence accumulates. University College London (UCL) and other institutions announced on October 22 that the trial had recruited its first participants.

The study will initially include two existing drugs: metformin, used to treat type 2 diabetes, and atomoxetine, used for attention deficit hyperactivity disorder (ADHD). The team plans to recruit 1,200 people to assess whether these drugs can ease difficulties with memory and thinking and help patients maintain everyday functioning. This is a clinical study testing new uses for the drugs, and no efficacy results from this trial are available yet.

AD-SMART uses a multi-arm, multi-stage adaptive platform design. Different drug groups share a placebo control group, reducing the duplication involved in setting up a separate trial for each drug. Interim analyses will also take place at scheduled times to determine which treatment groups continue and which stop for lack of benefit, while allowing other candidate drugs to join over time. Health Data Research UK noted that the platform could also evaluate newly developed drugs in the future.

According to trial information from the Alzheimer’s Society in the UK, this phase 3 study, sponsored by UCL, randomly assigns participants to a drug group or a placebo group. Participants, the relatives or friends accompanying them in the study, and the clinical team are all unaware of the assignments. Each person will participate for up to 18 months, continuing to receive their usual care while attending regular follow-up visits or receiving follow-up by telephone or video to monitor medication use and side effects.

Determining whether a drug helps requires more than looking at test values. Alzheimer’s Research UK explained that assessments cover memory, thinking and everyday activities, alongside brain magnetic resonance imaging and blood biomarkers to track changes in brain structure and related indicators. International experts and people with lived experience of dementia also contributed to the initial drug selection and study design, helping define which changes would be meaningful in patients’ lives.

The research network is still expanding. The first participants came from two NHS foundation trusts serving Cambridgeshire and Peterborough, and Surrey and Borders, with more than 30 NHS research sites planned overall. The team expects to complete the assessments of the first drugs in 2030 and add other drugs during the first four years of the study, allowing the platform to continue producing answers.

The organizing team estimates that this design could more than halve the time needed to evaluate treatments, but this remains an expectation about research efficiency, rather than a demonstrated outcome. Experience with existing drugs can provide a starting point for research, but it cannot directly establish their suitability for people with Alzheimer’s disease. Whether the platform can eliminate ineffective options more quickly, and whether the remaining drugs can deliver noticeable benefits, will depend on subsequent efficacy and safety data.

References

  1. University College London
  2. UK Dementia Research Institute
  3. Alzheimer’s Research UK
  4. Health Data Research UK
  5. Alzheimer’s Society